Prognostic biomarkers in renal cell carcinoma

References

• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335(12), 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med.353(23), 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Chow WH, Devesa SS, Warren JL et al. Rising incidence of renal cell cancer in the United States. JAMA281(17), 1628–1631 (1999).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163(2), 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol.24(35), 5601–5608 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Tsui KH, Shvarts O, Smith RB et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J. Urol.163(4), 1090–1095 (2000).
   PubMed Web of Science ®Google Scholar
• Sene AP, Hunt L, McMahon RF et al. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br. J. Urol.70(2), 125–134 (1992).
   PubMedGoogle Scholar
• Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol. Clin. North Am.20(2), 263–275 (1993).
   PubMed Web of Science ®Google Scholar
• Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol. Clin. North Am.20(2), 247–262 (1993).
   PubMed Web of Science ®Google Scholar
• Rabinovitch RA, Zelefsky MJ, Gaynor JJ et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol.12(1), 206–212 (1994).
   PubMed Web of Science ®Google Scholar
• Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J. Urol.154(1), 28–31 (1995).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet.7(1), 85–90 (1994).
   PubMed Web of Science ®Google Scholar
• Shuin T, Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res.54(11), 2852–2855 (1994).
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Kibel A, Gray S et al. Tumour suppression by the human von Hippel–Lindau gene product. Nat. Med.1(8), 822–826 (1995).
   PubMed Web of Science ®Google Scholar
• Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst.94(20), 1569–1575 (2002).
   PubMed Web of Science ®Google Scholar
• Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol.196(2), 186–193 (2002).
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399(6733), 271–275 (1999).
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA93(20), 10595–10599 (1996).
   PubMed Web of Science ®Google Scholar
• Na X, Wu G, Ryan CK et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 α expression in renal cell carcinomas. J. Urol.170(2 Pt 1), 588–592 (2003).
   PubMed Web of Science ®Google Scholar
• Fukata S, Inoue K, Kamada M et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer103(5), 931–942 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int. J. Urol.2(3), 156–160 (1995).
   PubMedGoogle Scholar
• Jacobsen J, Rasmuson T, Grankvist K et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol.163(1), 343–347 (2000).
   PubMed Web of Science ®Google Scholar
• Yildiz E, Gokce G, Kilicarslan H et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int.93(7), 1087–1093 (2004).
   PubMedGoogle Scholar
• Joo HJ, Oh DK, Kim YS et al. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int.93(3), 291–296 (2004).
   PubMedGoogle Scholar
• Lee JS, Kim HS, Jung JJ et al. Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J. Surg. Oncol.77(1), 55–60 (2001).
   PubMed Web of Science ®Google Scholar
• Gelb AB, Kim HS, Jung JJ et al. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer80(9), 1768–1775 (1997).
   PubMedGoogle Scholar
• MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology46(1), 27–30 (1995).
   PubMedGoogle Scholar
• Minardi D, Lucarini G, Mazzucchelli R et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J. Urol.174(4 Pt 1), 1208–1212 (2005).
   PubMed Web of Science ®Google Scholar
• Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene23(33), 5624–5631 (2004).
   PubMed Web of Science ®Google Scholar
• Liao SY, Aurelio ON, Jan K et al. Identification of the MN/CAIX protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res.57(14), 2827–2831 (1997).
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res.9(2), 802–811 (2003).
   PubMed Web of Science ®Google Scholar
• Shvarts O, Seligson D, Lam J et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol.173(3), 725–728 (2005).
   PubMed Web of Science ®Google Scholar
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res.11(10), 3714–3721 (2005).
   PubMed Web of Science ®Google Scholar
• Yao M, Tabuchi H, Nagashima Y et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol.205(3), 377–387 (2005).
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature351(6326), 453–456 (1991).
   PubMed Web of Science ®Google Scholar
• Cross SM, Sanchez CA, Morgan CA et al. A p53-dependent mouse spindle checkpoint. Science267(5202), 1353–1356 (1995).
   PubMed Web of Science ®Google Scholar
• Uhlman DL, Nguyen PL, Manivel JC et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl Cancer Inst.86(19), 1470–1475 (1994).
   PubMedGoogle Scholar
• Moch H, Sauter G, Gasser TC et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol. Res.25(Suppl 1), S25–S30 (1997).
   PubMedGoogle Scholar
• Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol.173(5), 1496–1501 (2005).
   PubMed Web of Science ®Google Scholar
• Girgin C, Tarhan H, Hekimgil M et al.p53 mutations and other prognostic factors of renal cell carcinoma. Urol. Int.66(2), 78–83 (2001).
   PubMedGoogle Scholar
• Shiina H, Igawa M, Urakami S et al. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur. Urol.31(1), 73–80 (1997).
   PubMedGoogle Scholar
• Bot FJ, Godschalk JC, Krishnadath KK et al. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int. J. Cancer57(5), 634–637 (1994).
   PubMedGoogle Scholar
• Hofmockel G, Wittmann A, Dammrich J et al. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res.16(6B), 3807–3811 (1996).
   PubMed Web of Science ®Google Scholar
• Papadopoulos I, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur. Urol.32(1), 110–117 (1997).
   PubMedGoogle Scholar
• Kramer BA, Gao X, Davis M et al. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J. Am. Coll. Surg.201(4), 565–570 (2005).
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bozoky B, Kovacs G et al. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scan. J. Urol. Nephrol.35(1), 15–20 (2001).
   PubMedGoogle Scholar
• Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell69(7), 1237–1245 (1992).
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D et al. The p53–mdm-2 autoregulatory feedback loop. Genes Dev.7(7A), 1126–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Haitel A, Wiener HG, Baethge U et al. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res.6(5), 1840–1844 (2000).
   PubMed Web of Science ®Google Scholar
• Hedberg Y, Davoodi E, Ljungberg B et al. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int. J. Cancer102(6), 601–607 (2002).
   PubMedGoogle Scholar
• Migita T, Oda Y, Naito S et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer94(4), 973–979 (2002).
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Lipponen P, Ala-Opas M et al. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br. J. Cancer80(12), 2001–2007 (1999).
   PubMedGoogle Scholar
• Hedberg Y, Davoodi E, Roos G et al. Cyclin-D1 expression in human renal-cell carcinoma. Int. J. Cancer84(3), 268–272 (1999).
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science275(5308), 1943–1947 (1997).
   PubMed Web of Science ®Google Scholar
• Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer99(1), 53–57 (2002).
   PubMed Web of Science ®Google Scholar
• Velickovic M, Delahunt B, McIver B et al. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod. Pathol.15(5), 479–485 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer91(2), 219–224 (2001).
   PubMedGoogle Scholar
• Shin Lee J, Seok Kim H, Bok Kim Y et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol.84(3), 166–172 (2003).
   PubMedGoogle Scholar
• Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res.10(16), 5464–5471 (2004).
   PubMed Web of Science ®Google Scholar
• Rioux-Leclercq N, Turlin B, Bansard J et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology55(4), 501–505 (2000).
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Hahn HA, Katalinic A et al. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer77(1), 164–171 (1996).
   PubMed Web of Science ®Google Scholar
• Haitel A, Wiener HG, Migschitz B et al. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas? Am. J. Clin. Pathol.107(2), 229–235 (1997).
   PubMed Web of Science ®Google Scholar
• Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol.27(5), 612–624 (2003).
   PubMed Web of Science ®Google Scholar
• Cronin KJ, Williams NN, Kerin MJ et al. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J. Urol.152(3), 834–836 (1994).
   PubMed Web of Science ®Google Scholar
• Hofmockel G, Tsatalpas P, Muller H et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer76(2), 296–306 (1995).
   PubMed Web of Science ®Google Scholar
• Abou-Rebyeh H, Borgmann V, Nagel R et al. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer92(9), 2280–2285 (2001).
   PubMedGoogle Scholar
• Di Silverio F, Casale P, Colella D et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer88(4), 835–843 (2000).
   PubMedGoogle Scholar
• Jochum W, Schroder S, al-Taha R et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer77(3), 514–521 (1996).
   PubMed Web of Science ®Google Scholar
• Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br. J. Cancer71(2), 376–379 (1995).
   PubMedGoogle Scholar
• Shimazui T, Oosterwijk E, Akaza H et al. Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin. Cancer Res.4(10), 2419–2424 (1998).
   PubMedGoogle Scholar
• Shimazui T, Bringuier PP, van Berkel H et al. Decreased expression of α-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int. J. Cancer74(5), 523–528 (1997).
   PubMedGoogle Scholar
• Slaton JW, Inoue K, Perrotte P et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am. J. Pathol.158(2), 735–743 (2001).
   PubMed Web of Science ®Google Scholar
• Gilcrease MZ, Guzman-Paz M, Niehans G et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer86(11), 2320–2326 (1999).
   PubMed Web of Science ®Google Scholar
• Paradis V, Ferlicot S, Ghannam E et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J. Urol.161(6), 1984–1987 (1999).
   PubMedGoogle Scholar
• Li N, Tsuji M, Kanda K et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int.85(4), 514–518 (2000).
   PubMedGoogle Scholar
• Seligson DB, Pantuck AJ, Liu X et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res.10(8), 2659–2669 (2004).
   PubMed Web of Science ®Google Scholar
• Nieminen M, Henttinen T, Merinen M et al. Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol.8(2), 156–162 (2006).
   PubMed Web of Science ®Google Scholar
• Sabo E, Miselevich I, Bejar J et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br. J. Urol.80(6), 864–868 (1997).
   PubMedGoogle Scholar
• Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer80(1–2), 301–308 (1999).
   PubMedGoogle Scholar
• Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am. J. Clin. Pathol.118(1), 47–51 (2002).
   PubMed Web of Science ®Google Scholar
• Kraus S, Abel PD, Nachtmann C et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum. Pathol.33(1), 60–67 (2002).
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med.5(12), 1365–1369 (1999).
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. [erratum appears in Nat. Med.8(9), 1039 (2002)]. Nat. Med.8(8), 793–800 (2002).
   Google Scholar
• Brown JA, Dorfman DM, Ma FR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol.170(3), 1257–1266 (2003).
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res.10(15), 5094–5100 (2004).
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res.63(21), 7462–7467 (2003).
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res.64(3), 1140–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Webster WS, Cheville JC et al. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology66(5 Suppl.), 10–14 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA101(49), 17174–17179 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer104(10), 2084–2091 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res.66(7), 3381–3385 (2006).
   PubMed Web of Science ®Google Scholar
• Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity18(6), 849–861 (2003).
   PubMed Web of Science ®Google Scholar
• Choi IH, Zhu G, Sica GL et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol.171(9), 4650–4654 (2003).
   PubMed Web of Science ®Google Scholar
• Salceda S, Tang T, Kmet M et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell. Res.306(1), 128–141 (2005).
   PubMed Web of Science ®Google Scholar
• Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA103(27), 10391–10396 (2006).
   PubMed Web of Science ®Google Scholar
• Mueller-Pillasch F, Pohl B, Wilda M et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev.88(1), 95–99 (1999).
   PubMed Web of Science ®Google Scholar
• Nielsen J, Christiansen J, Lykke-Andersen J et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol.19(2), 1262–1270 (1999).
   PubMed Web of Science ®Google Scholar
• Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene14(22), 2729–2733 (1997).
   PubMedGoogle Scholar
• Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br. J. Cancer88(6), 887–894 (2003).
   PubMedGoogle Scholar
• Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol.29(2), 188–195 (2005).
   PubMedGoogle Scholar
• Liao B, Hu Y, Herrick DJ et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem.280(18), 18517–18524 (2005).
   PubMed Web of Science ®Google Scholar
• Yaniv K, Fainsod A, Kalcheim C et al. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development130(23), 5649–5661 (2003).
   PubMedGoogle Scholar
• Vikesaa J, Hansen TV, Jonson L et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J.25(7), 1456–1468 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol.7(7), 556–564 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao H, Ljungber B, Grankvist K et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med.3(1), e13 (2006).
   PubMed Web of Science ®Google Scholar
• Moch H, Schraml P, Bubendorf L et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol.154(4), 981–986 (1999).
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Franzke A, Buer J et al. Prognostic impact of in vivosoluble cell adhesion molecules in metastatic renal cell carcinoma. Br. J. Cancer79(11–12), 1742–1745 (1999).
   PubMed Web of Science ®Google Scholar
• Rasmuson T, Grankvist K, Jacobsen J et al. Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol.43(8), 744–748 (2004).
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yossepowitch O, Pettus JA et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J. Clin. Oncol.24(19), 3101–3106 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol.2(8), 416–422 (2005).
   PubMedGoogle Scholar
• Takahashi M, Sugimura J, Yang X et al. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv. Cancer Res.89, 157–181 (2003).
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Cheville JC et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor Stage, SIze, Grade and Necrosis: the SSIGN score. J. Urol.168(6), 2395–2400 (2002).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol.19(6), 1649–1657 (2001).
   PubMed Web of Science ®Google Scholar